抗中性粒细胞胞质抗体相关血管炎患者股骨头坏死的患病率与危险因素:多中心队列研究
该多中心队列回顾性评估186例抗中性粒细胞胞质抗体相关血管炎(AAV)患者,在初始缓解诱导治疗(RIT)6个月后行双髋关节X线和MRI筛查,18%诊断为股骨头坏死(ONFH);RIT第90天泼尼松龙剂量≥20 mg/天为ONFH独立危险因素(OR 1.072,95%CI 1.017–1.130,p=0.009)。
要点
- 186例AAV患者中33例(18%)诊断ONFH,其中55%无症状、64%为双侧。
- 76%的ONFH关节处于塌陷前阶段(≤2期),但其中56%已属未来塌陷风险类型(≥C-1)。
- RIT第90天泼尼松龙剂量≥20 mg/天为ONFH独立危险因素(OR 1.072,95%CI 1.017–1.130,p=0.009)。
核心结论
- 18%的AAV患者发生ONFH,三分之二的ONFH关节已处于塌陷阶段或存在未来塌陷风险。
- RIT第90天泼尼松龙剂量≥20 mg/天是ONFH的独立危险因素。
- 作者认为,在RIT中快速减少糖皮质激素并通过MRI早期检测塌陷前ONFH,可能减少并干预AAV患者ONFH的发展。
研究设计与样本
- 多中心队列研究,回顾性评估186例AAV患者。
- 纳入在初始缓解诱导治疗(RIT)6个月后接受双侧髋关节X线和MRI筛查的患者。
主要发现
- 186例AAV患者中33例(18%)诊断为ONFH。
- ONFH患者中55%无症状,64%为双侧ONFH。
- ONFH关节中76%处于塌陷前阶段(≤2期),24%处于塌陷阶段(≥3期)。
- 塌陷前阶段关节中56%已属未来塌陷风险类型(≥C-1);即使无症状ONFH患者,其塌陷前阶段关节中39%为≥C-1型。
- RIT第90天泼尼松龙剂量≥20 mg/天为ONFH独立危险因素(OR 1.072,95%CI 1.017–1.130,p=0.009);利妥昔单抗使用为显著有益因素(p=0.019),但多因素分析否定其显著性(p=0.257)。
关键数值与推荐
- ONFH诊断依据双侧髋关节X线和MRI筛查。
- ONFH分期采用塌陷前阶段(≤2期)与塌陷阶段(≥3期)分类,塌陷风险类型采用≥C-1型定义。
临床怎么用
- 作者认为,在RIT中快速减少糖皮质激素并早期通过MRI检测塌陷前ONFH,可能减少并干预AAV患者ONFH的发展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine the prevalence and risk factors for osteonecrosis of the femoral head (ONFH) in a multicentre cohort of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: One hundred and eighty-six AAV patients who underwent radiographs and MRI screening of bilateral hip joints at more than 6 months after initial remission induction therapy (RIT) were retrospectively assessed for the presence of ONFH. RESULTS: Among 186 AAV patients, 33 (18%) were diagnosed with ONFH. Among the patients with ONFH, 55% were asymptomatic and 64% had bilateral ONFH. Seventy-six per cent of ONFH joints were in precollapse stages (stage ≤2), whereas 24% of ONFH joints were in collapse stages (stage ≥3). Moreover, 56% of the precollapse stage joints were already at risk of future collapse (type ≥C-1). Even in asymptomatic ONFH patients, 39% of the precollapse stage joints were type ≥C-1. Prednisolone dose of ≥20 mg/day on day 90 of RIT was an independent risk factor for ONFH in AAV patients (OR 1.072, 95% CI 1.017 to 1.130, p=0.009). Rituximab use was a significant beneficial factor against ONFH (p=0.019), but the multivariate analysis rejected its significance (p=0.257). CONCLUSION: Eighteen per cent of AAV patients developed ONFH, and two-thirds of the ONFH joints were already in collapse stages or at risk of future collapse. Prednisolone dose of ≥20 mg/day on day 90 of RIT was an independent risk factor for ONFH. A rapid reduction of glucocorticoids in RIT and early detection of precollapse ONFH by MRI may decrease and intervene ONFH development in AAV patients.
引用
- Mimura N, Iwamoto T, Furuta S, et al. Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study. RMD Open. 2023. PMID: 36849207. doi:10.1136/rmdopen-2022-002787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。